Cat. No.: HY-10373

Trimetrexate

(Synonyms: CI-898)

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Trimetrexate (CI-898) is an antibiotic, also a potent and orally active dihydrofolate reductase (DHFR) inhibitor, reducing the production of DNA and RNA precursors and leading to cell death, with IC₅₀ values of 4.74 nM and 1.35 nM for human DHFR and Toxoplasma gondii DHFR. Trimetrexate can also inhibit the growth of various cancer cells. Trimetrexate can be used for researching Pneumocystis carinii pneumonia (PCP) and cancer.

For research use only. We do not sell to patients.

Purity: 99.60%
CAS No.: 52128-35-5
Formula: C₁₉H₂₃N₅O₃
Molecular Weight:369.42

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Trimetrexate Chemical Structure

CAS No.: 52128-35-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

Toxoplasma

All Antibiotic Isoforms :

All Parasite Isoforms :

All DNA/RNA Synthesis Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5.3 nM Compound: TMX	Cytotoxic activity evaluated against A549 tumor cells Cytotoxic activity evaluated against A549 tumor cells	[PMID: 8632413]
D54 cell line	IC₅₀	60 nM Compound: TMX	Cytotoxic Activity was evaluated against D54 tumor cells Cytotoxic Activity was evaluated against D54 tumor cells	[PMID: 8632413]
Daoy	IC₅₀	12 nM Compound: TMX	Cytotoxic activity was evaluated against Daoy tumor cells Cytotoxic activity was evaluated against Daoy tumor cells	[PMID: 8632413]
HCT-116	GI₅₀	0.01 μM Compound: TMX	Growth inhibitory activity against human HCT116 cell line Growth inhibitory activity against human HCT116 cell line	[PMID: 15267250]
HCT-116	GI₅₀	19 μM Compound: TMX	Growth inhibitory activity against human HCT116 cell line in presence of Hypoxanthine thymidine(HT) Growth inhibitory activity against human HCT116 cell line in presence of Hypoxanthine thymidine(HT)	[PMID: 15267250]
HCT-8	IC₅₀	1.8 nM Compound: TMX	Activity was evaluated against HCT-8 tumor cells Activity was evaluated against HCT-8 tumor cells	[PMID: 8632413]
HT-29	GI₅₀	0.01 μM Compound: TMX	Growth inhibitory activity against human HT-29 cell line Growth inhibitory activity against human HT-29 cell line	[PMID: 15267250]
HT-29	GI₅₀	21 μM Compound: TMX	Growth inhibitory activity against human HT-29 cell line in presence of Hypoxanthine thymidine(HT) Growth inhibitory activity against human HT-29 cell line in presence of Hypoxanthine thymidine(HT)	[PMID: 15267250]
IGROV-1	IC₅₀	12 nM Compound: trimetrexate	Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells	[PMID: 18680275]
IGROV-1	IC₅₀	8.6 nM Compound: trimetrexate	Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid	[PMID: 18680275]
KB	IC₅₀	155 nM Compound: trimetrexate	Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid	[PMID: 18680275]
KB	IC₅₀	58 nM Compound: trimetrexate	Antiproliferative activity against human RFC and FRalpha expressing human KB cells Antiproliferative activity against human RFC and FRalpha expressing human KB cells	[PMID: 18680275]
P388	IC₅₀	2.7 nM Compound: TMX	Cytotoxic activity was evaluated against P388D1 tumor cells Cytotoxic activity was evaluated against P388D1 tumor cells	[PMID: 8632413]
R2	IC₅₀	6.7 nM Compound: trimetrexate	Antiproliferative activity against human RFC expressing Chinese hamster R2 cells Antiproliferative activity against human RFC expressing Chinese hamster R2 cells	[PMID: 18680275]
SCC-25	IC₅₀	8 nM Compound: 3	Tested for inhibitory concentration against human SCC25 cell line Tested for inhibitory concentration against human SCC25 cell line	[PMID: 8035423]
SCC-7	IC₅₀	6.3 nM Compound: 3	Tested for inhibitory concentration against SCC-VII murine squamous carcinoma cell line Tested for inhibitory concentration against SCC-VII murine squamous carcinoma cell line	[PMID: 8035423]
U-373MG ATCC	IC₅₀	9.6 nM Compound: TMX	Cytotoxic activity was evaluated against U373MG tumor cells Cytotoxic activity was evaluated against U373MG tumor cells	[PMID: 8632413]
U-87MG ATCC	IC₅₀	11 nM Compound: TMX	Cytotoxic activity was evaluated against U87MG tumor cells Cytotoxic activity was evaluated against U87MG tumor cells	[PMID: 8632413]
Vero	IC₅₀	16 nM Compound: TMX	Cytotoxic Activity was evaluated against Vero tumor cells Cytotoxic Activity was evaluated against Vero tumor cells	[PMID: 8632413]

In Vitro

Trimetrexate (0.1 μM, 18 h) completely inhibits proliferation of toxoplasma in murine macrophages^[3].
Trimetrexate (1 μM) can cross the toxoplasma cell membrane and rapidly reaches high intracellular concentrations (108 pmol/10⁷ cells within 10 min) ^[3].
Trimetrexate (0.1 mM; 24 h) inhibits cell growth by 50-60% in SNU-C4 and NCI-H630 cell lines^[5].
Trimetrexate (1 and 10 mM; 24 h) produces lethality and inhibits DHFR in C4 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[5]

Cell Line:

SNU-C4 and NCI-H630
Concentration:

0.1 mM
Incubation Time:

24 h
Result:

Inhibited cell growth by 50-60% in both cell lines.

Cell Proliferation Assay^[5]

Cell Line:

C4 cells
Concentration:

1 and 10 mM
Incubation Time:

24 h
Result:

Produced 42% and 50% lethality at 1 and 10 mM, respectively.

In Vivo

Trimetrexate (180 mg/kg or 30 mg/kg; p.o. or i.p.; daily) extends the median survival of the toxoplasma infected mice and shows antitoxoplasma activity^[3]. Trimetrexate (0-30 mg/kg; i.v.; once daily for 5days) shows chronic toxicity in rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Toxoplasma infected female BALB/c mice weighing about 20 g^[3]
Dosage:

180 mg/kg or 30 mg/kg
Administration:

180 mg/kg per day orally in the drinking water or 30 mg/kg per day i.p.
Result:

Extended the median survival of the infected mice to 10 d (p.o.) or 19 d (i.p.).

Animal Model:

Charles River Wistar Crl(WI)BR rats weighing approximately 150 to 200 g^[4]
Dosage:

0, 1, 10, or 30 mg/kg
Administration:

Intravenous injection, once daily for 5 consecutive days followed by a 23-day recovery period
Result:

Showed chronic toxicity, the testicular changes persisting during the course of multiple cycles of dosing were not reversible within 21 days, but required an additional 56 days for essentially complete recovery.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 52128-35-5
Appearance Solid
Molecular Weight 369.42
Formula C₁₉H₂₃N₅O₃
Color Off-white to yellow
SMILES

NC1=C(C(C)=C2CNC3=CC(OC)=C(OC)C(OC)=C3)C(C=C2)=NC(N)=N1
Synonyms

CI-898
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

Nat Commun

IQGAP3 bridges matrix stiffness with glioma stem cell maintenance and radioresistance by stabilizing SOX2. [Abstract]

2026 Jun 6. PMID: 42251046
Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
Antimicrob Agents Chemother

Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus. [Abstract]

2024 Oct 29:e0105124. PMID: 39470195

Solvent & Solubility

In Vitro:

DMSO : ≥ 61.5 mg/mL (166.48 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7069 mL

13.5347 mL

27.0695 mL

5 mM

0.5414 mL

2.7069 mL

5.4139 mL

10 mM

0.2707 mL

1.3535 mL

2.7069 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 40 mg/mL (108.28 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019 Feb 14;62(3):1562-1576. [Content Brief]

[2]. Fulton, B., et al. Trimetrexate. Drugs 49, 563–576 (1995). [Content Brief]

[3]. Allegra CJ, et al. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest. 1987 Feb;79(2):478-82. [Content Brief]

[4]. Dethloff LA, et al. Chronic toxicity of the anticancer agent trimetrexate in rats. Fundam Appl Toxicol. 1992 Jul;19(1):6-14. [Content Brief]

[5]. Grem JL, Voeller DM, Geoffroy F, Horak E, Johnston PG, Allegra CJ. Determinants of trimetrexate lethality in human colon cancer cells. Br J Cancer. 1994 Dec;70(6):1075-84. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7069 mL	13.5347 mL	27.0695 mL	67.6736 mL
	5 mM	0.5414 mL	2.7069 mL	5.4139 mL	13.5347 mL
	10 mM	0.2707 mL	1.3535 mL	2.7069 mL	6.7674 mL
	15 mM	0.1805 mL	0.9023 mL	1.8046 mL	4.5116 mL
	20 mM	0.1353 mL	0.6767 mL	1.3535 mL	3.3837 mL
	25 mM	0.1083 mL	0.5414 mL	1.0828 mL	2.7069 mL
	30 mM	0.0902 mL	0.4512 mL	0.9023 mL	2.2558 mL
	40 mM	0.0677 mL	0.3384 mL	0.6767 mL	1.6918 mL
	50 mM	0.0541 mL	0.2707 mL	0.5414 mL	1.3535 mL
	60 mM	0.0451 mL	0.2256 mL	0.4512 mL	1.1279 mL
	80 mM	0.0338 mL	0.1692 mL	0.3384 mL	0.8459 mL
	100 mM	0.0271 mL	0.1353 mL	0.2707 mL	0.6767 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Trimetrexate

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Pancreatic Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Amino Acid Metabolism Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Chinese Baijiu Compound Library

Publications Citing Use of MedChemExpress (MCE) Trimetrexate

All Antibiotic Isoforms

All Parasite Isoforms

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Trimetrexate Related Classifications

Cat. No.: HY-10373